ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade

Chen, Tingting; Yu, Tong; Zhuang, Shuping; Geng, Yiding; Xue, Junwen; Wang, Jiayi; Ai, Liqiang; Chen, Bo; Zhao, Zhangxiang; Li, Yawei; Wang, Jinghao; Liang, Haihai; Xu, Yan*; Gu, Yunyan*哈尔滨医科大学; 1; y
British Journal of Cancer2022-9-1DOI: 10.1038/s41416-022-01836-0
2被引9阅读
引用收藏
分享

摘要

Background Mutations in BRCA1 or BRCA2 (BRCA1/2) cause homologous recombination deficiency (HRD). Ovarian cancer (OvCa) patients harbouring HRD beyond BRCA1/2 mutation result in a state referred to as "BRCAness". OvCa with BRCAness could benefit from PARP inhibitors. This study aims to identify a signature to detect the BRCAness population at the transcriptome level. Methods We used a rank-based algorithm to develop a qualitative BRCAness signature for OvCa. Upregulation of CXCL1 with downregulation of SV2A and upregulation of LY9 with downregulation of CHRNB3 were constructed as the BRCAness signature (2 gene pairs, 2-GPS) for OvCa. Results OvCa samples that were classified as BRCAness by 2-GPS showed improved overall survival, progression-free survival and exhibited increased multi-omics alterations in homologous recombination genes and enhanced sensitivity to immune checkpoint blockade. BRCAness cells were sensitive to PARP inhibitors. By biological experiments, we validated SKOV3 cells and patients with HRD exhibited higher expression of CXCL1 than SV2A and higher expression of LY9 than CHRNB3 at mRNA level. Both SKOV3 and A2780 with HRD were sensitive to mitomycin C, cisplatin and olaparib. Conclusions In conclusion, 2-GPS could robustly predict BRCAness OvCa at the individual level and extend the population who may benefit from PARP inhibitors.

学科与关键词

关键词
HOMOLOGOUS RECOMBINATION DEFICIENCYCHEMOTHERAPY
相关
加载中…
  • Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
    Guffanti, Federica; Mengoli, Ilaria; Damia, Giovanna*Frontiers in Oncology, 2024, 14: 1405361.被引 2
  • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
    Zhang, Meng; Ma, Si-Cong; Tan, Jia-Le; Wang, Jian; Bai, Xue; Dong, Zhong-Yi*; Zhang, Qing-Xue*Frontiers in Oncology, 2021, 11: 772604.被引 1
  • Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
    Setor, Amuzu; Euridice, Carmona; Anne-Marie, Mes-Masson; Celia M. T., Greenwood; Patricia N., Tonin; Jiannis, RagoussisCancers, 2021, 13(6): 1296.
查看全部 →

发表信息

论文状态
公开发表
期刊
British Journal of Cancer
发表日期
2022-09-01
卷期
第 127 卷, 第 5 期
页码
916-926
DOI
10.1038/s41416-022-01836-0
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [61673143, 81673036]; Outstanding Youth Foundation of Heilongjiang Province of China [YQ2021H005]; HMU Marshal Initiative Funding [HMUMIF-21023]

作者

  • C

    Chen, Tingting (第一作者)

    harbin med univ

  • Y

    Yu, Tong

    harbin med univ

查看全部 14 位作者收起作者
  • Z

    Zhuang, Shuping

    harbin med univ

  • G

    Geng, Yiding

    harbin med univ

  • X

    Xue, Junwen

    harbin med univ

  • W

    Wang, Jiayi

    harbin med univ

  • A

    Ai, Liqiang

    harbin med univ

  • C

    Chen, Bo

    harbin med univ

  • Z

    Zhao, Zhangxiang

    1

  • L

    Li, Yawei

    harbin med univ

  • W

    Wang, Jinghao

    1

  • L

    Liang, Haihai

    1 · harbin med univ

  • X

    Xu, Yan (通讯)

    harbin med univ

  • G

    Gu, Yunyan (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417